Mary Wilson
Well-known member
Article posted: 1 October 2021
Authored by: Jeff Boden, Ph.D.
On October 1[SUP]st[/SUP], Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. They report at the interim analysis that “molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012.” Formal publication of the data is pending.
Molnupiravir was named by Kaleio in the early days of the coronavirus pandemic. The primary mechanism of action of molnupiravir is induction of lethal mutagenesis by incorporation of the 5’-monophosphate metabolite into the viral RNA genome. Because molnupiravir is resistant to the proofreading exoribonuclease encoded by coronaviruses, it is able to prevent viral propagation via viral error catastrophe, for which no defined nomenclature exists in the INN/USAN system.
https://www.idstewardship.com/molnupiravir-new-covid-antiviral-named-thors-hammer/
Authored by: Jeff Boden, Ph.D.
On October 1[SUP]st[/SUP], Merck and Ridgeback Biotherapeutics announced that molnupiravir (MK-4482, EIDD-2801), an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death at a planned interim analysis of the Phase 3 trial in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19. They report at the interim analysis that “molnupiravir reduced the risk of hospitalization or death by approximately 50%; 7.3% of patients who received molnupiravir were either hospitalized or died through Day 29 following randomization (28/385), compared with 14.1% of placebo-treated patients (53/377); p=0.0012.” Formal publication of the data is pending.
Molnupiravir was named by Kaleio in the early days of the coronavirus pandemic. The primary mechanism of action of molnupiravir is induction of lethal mutagenesis by incorporation of the 5’-monophosphate metabolite into the viral RNA genome. Because molnupiravir is resistant to the proofreading exoribonuclease encoded by coronaviruses, it is able to prevent viral propagation via viral error catastrophe, for which no defined nomenclature exists in the INN/USAN system.
https://www.idstewardship.com/molnupiravir-new-covid-antiviral-named-thors-hammer/